The mention of developing other applications and products and the price capping give me the felling a cap raising may be on the cards.
It goes without saying they will be doing ongoing R&D, why make a point of it?
It was said that there was enough money until at least next year but that was before the FDA gave VitroGrow a bio classification. Do they now need more money than originally thought for further R&D and approval?
Also how long will it take to achieve $15 million in sales, which for a 30% net margin to TIS is what’s needed to support a PE of 20. At say $500 per patient, this would be 30000 patients. Seems doable in the next few years but hard to know?
- Forums
- ASX - By Stock
- TIS
- vitrogro ecm meets ce mark requirements
vitrogro ecm meets ce mark requirements , page-22
-
-
- There are more pages in this discussion • 28 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add TIS (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
HAR
HARANGA RESOURCES LIMITED.
Peter Batten, MD
Peter Batten
MD
Previous Video
Next Video
SPONSORED BY The Market Online